Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Structural basis of ECF-σ-factor-dependent transcription initiation.

Lin W, Mandal S, Degen D, Cho MS, Feng Y, Das K, Ebright RH.

Nat Commun. 2019 Feb 12;10(1):710. doi: 10.1038/s41467-019-08443-3.

2.

Renal recovery in a dialysis-dependent patient with end-stage kidney disease secondary to analgesic nephropathy.

Park YA, Harris G, Degen DA.

Nephrology (Carlton). 2018 Jul;23(7):705-706. doi: 10.1111/nep.13171. No abstract available.

PMID:
30133974
3.

Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3).

Lin W, Das K, Degen D, Mazumder A, Duchi D, Wang D, Ebright YW, Ebright RY, Sineva E, Gigliotti M, Srivastava A, Mandal S, Jiang Y, Liu Y, Yin R, Zhang Z, Eng ET, Thomas D, Donadio S, Zhang H, Zhang C, Kapanidis AN, Ebright RH.

Mol Cell. 2018 Apr 5;70(1):60-71.e15. doi: 10.1016/j.molcel.2018.02.026. Epub 2018 Mar 29.

PMID:
29606590
4.

Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase.

Maffioli SI, Zhang Y, Degen D, Carzaniga T, Del Gatto G, Serina S, Monciardini P, Mazzetti C, Guglierame P, Candiani G, Chiriac AI, Facchetti G, Kaltofen P, Sahl HG, Dehò G, Donadio S, Ebright RH.

Cell. 2017 Jun 15;169(7):1240-1248.e23. doi: 10.1016/j.cell.2017.05.042.

5.

Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition.

Lin W, Mandal S, Degen D, Liu Y, Ebright YW, Li S, Feng Y, Zhang Y, Mandal S, Jiang Y, Liu S, Gigliotti M, Talaue M, Connell N, Das K, Arnold E, Ebright RH.

Mol Cell. 2017 Apr 20;66(2):169-179.e8. doi: 10.1016/j.molcel.2017.03.001. Epub 2017 Apr 6.

6.

Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.

Walker SS, Degen D, Nickbarg E, Carr D, Soriano A, Mandal M, Painter RE, Sheth P, Xiao L, Sher X, Murgolo N, Su J, Olsen DB, Ebright RH, Young K.

ACS Chem Biol. 2017 May 19;12(5):1346-1352. doi: 10.1021/acschembio.6b01133. Epub 2017 Mar 31.

7.

Predictive performance of different kidney function estimation equations in lung transplant patients.

Degen DA, Janardan J, Barraclough KA, Schneider HG, Barber T, Barton H, Snell G, Levvey B, Walker RG.

Clin Biochem. 2017 May;50(7-8):385-393. doi: 10.1016/j.clinbiochem.2017.01.008. Epub 2017 Jan 17.

PMID:
28108166
8.

Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma.

Degen D, Kanellis J, Hughes P, Barit D, Ierino F.

Nephrology (Carlton). 2016 Jun;21(6):528. doi: 10.1111/nep.12626. No abstract available.

PMID:
27188412
9.

Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles.

Feng Y, Degen D, Wang X, Gigliotti M, Liu S, Zhang Y, Das D, Michalchuk T, Ebright YW, Talaue M, Connell N, Ebright RH.

Structure. 2015 Aug 4;23(8):1470-1481. doi: 10.1016/j.str.2015.06.009. Epub 2015 Jul 16.

10.

Pivotal role of choline metabolites in remyelination.

Skripuletz T, Manzel A, Gropengießer K, Schäfer N, Gudi V, Singh V, Salinas Tejedor L, Jörg S, Hammer A, Voss E, Vulinovic F, Degen D, Wolf R, Lee DH, Pul R, Moharregh-Khiabani D, Baumgärtner W, Gold R, Linker RA, Stangel M.

Brain. 2015 Feb;138(Pt 2):398-413. doi: 10.1093/brain/awu358. Epub 2014 Dec 17.

PMID:
25524711
11.

Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp.

Hassan HM, Degen D, Jang KH, Ebright RH, Fenical W.

J Antibiot (Tokyo). 2015 Mar;68(3):206-9. doi: 10.1038/ja.2014.122. Epub 2014 Sep 17. No abstract available.

12.

Synthesis and evaluation of novel analogues of ripostatins.

Tang W, Liu S, Degen D, Ebright RH, Prusov EV.

Chemistry. 2014 Sep 15;20(38):12310-9. doi: 10.1002/chem.201403176. Epub 2014 Aug 11.

13.

Transcription inhibition by the depsipeptide antibiotic salinamide A.

Degen D, Feng Y, Zhang Y, Ebright KY, Ebright YW, Gigliotti M, Vahedian-Movahed H, Mandal S, Talaue M, Connell N, Arnold E, Fenical W, Ebright RH.

Elife. 2014 Apr 30;3:e02451. doi: 10.7554/eLife.02451.

14.

GE23077 binds to the RNA polymerase 'i' and 'i+1' sites and prevents the binding of initiating nucleotides.

Zhang Y, Degen D, Ho MX, Sineva E, Ebright KY, Ebright YW, Mekler V, Vahedian-Movahed H, Feng Y, Yin R, Tuske S, Irschik H, Jansen R, Maffioli S, Donadio S, Arnold E, Ebright RH.

Elife. 2014 Apr 22;3:e02450. doi: 10.7554/eLife.02450.

15.

Erysipelas of the thigh and the gluteal region: retrospective multicenter analysis of a very rare entity in 39 patients.

Glatz M, Degen D, French LE, Aberer W, Müllegger RR.

Dermatology. 2012;225(3):277-83. doi: 10.1159/000345619. Epub 2012 Dec 19.

16.

Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Srivastava A, Degen D, Ebright YW, Ebright RH.

Antimicrob Agents Chemother. 2012 Dec;56(12):6250-5. doi: 10.1128/AAC.01060-12. Epub 2012 Sep 24.

17.

New target for inhibition of bacterial RNA polymerase: 'switch region'.

Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopadhyay J, Ebright YW, Zozula A, Shen J, Sengupta S, Niedfeldt RR, Xin C, Kaneko T, Irschik H, Jansen R, Donadio S, Connell N, Ebright RH.

Curr Opin Microbiol. 2011 Oct;14(5):532-43. doi: 10.1016/j.mib.2011.07.030. Epub 2011 Aug 19. Review.

18.

Iminohydantoin lesion induced in DNA by peracids and other epoxidizing oxidants.

Ye W, Sangaiah R, Degen DE, Gold A, Jayaraj K, Koshlap KM, Boysen G, Williams J, Tomer KB, Mocanu V, Dicheva N, Parker CE, Schaaper RM, Ball LM.

J Am Chem Soc. 2009 May 6;131(17):6114-23. doi: 10.1021/ja8090752.

19.

A 2-iminohydantoin from the oxidation of guanine.

Ye W, Sangaiah R, Degen DE, Gold A, Jayaraj K, Koshlap KM, Boysen G, Williams J, Tomer KB, Ball LM.

Chem Res Toxicol. 2006 Apr;19(4):506-10. Erratum in: Chem Res Toxicol. 2006 Jun;19(6):887.

PMID:
16608161
20.

An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel.

Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL.

Cancer Chemother Pharmacol. 1997;40(1):81-6.

PMID:
9137535
21.
22.

Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients.

Izquierdo MA, Degen D, Sypek JP, Von Hoff DD.

Anticancer Drugs. 1996 May;7(3):275-80.

PMID:
8792000
23.

Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients.

Izquierdo MA, Degen D, Myers L, Levitt DJ, Von Hoff DD.

Ann Oncol. 1995 Nov;6(9):927-32.

PMID:
8624297
24.

Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.

Cobb PW, Degen DR, Clark GM, Chen SF, Kuhn JG, Gross JL, Kirshenbaum MR, Sun JH, Burris HA 3rd, Von Hoff DD.

J Natl Cancer Inst. 1994 Oct 5;86(19):1462-5.

PMID:
8089865
25.

Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.

Martin KJ, Chen SF, Clark GM, Degen D, Wajima M, Von Hoff DD, Kaddurah-Daouk R.

J Natl Cancer Inst. 1994 Apr 20;86(8):608-13.

PMID:
8145276
26.

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA 3rd, Degen D, Von Hoff DD.

Anticancer Drugs. 1994 Apr;5(2):202-6.

PMID:
8049503
27.

In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).

el-Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD.

Anticancer Drugs. 1993 Feb;4(1):19-25.

PMID:
8457709
28.

Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer.

Nielsen JL, Walsh JT, Degen DR, Drabek SM, McGill JR, von Hoff DD.

Cancer Genet Cytogenet. 1993 Feb;65(2):120-4.

PMID:
8384074
29.

In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.

Marshall MV, Marshall MH, Degen DR, Roodman GD, Kuhn JG, Ross ME, Von Hoff DD.

Stem Cells. 1993 Jan;11(1):62-9.

PMID:
8457783
30.

In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.

Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD.

Eur J Cancer. 1993;29A(3):423-5.

PMID:
8398345
31.

Lack of effects of recombinant human interleukin-4 on in vitro colony formation of freshly explanted human tumor cells.

Hanauske AR, Degen D, Marshall MH, Trotta PP, Von Hoff DD.

Invest New Drugs. 1992 Nov;10(4):269-73.

PMID:
1487400
32.

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD.

Anticancer Drugs. 1992 Apr;3(2):143-6.

PMID:
1525392
33.

Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Banks P, Stuckey J, Leahy M, Von Hoff DD.

J Immunother (1991). 1992 Apr;11(3):155-8.

PMID:
1515420
34.

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.

Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD.

Anticancer Drugs. 1992 Apr;3(2):121-4.

PMID:
1356030
35.

Preclinical activity of ilmofosine against human tumor colony forming units in vitro.

Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff DD.

Anticancer Drugs. 1992 Feb;3(1):43-6.

PMID:
1623215

Supplemental Content

Support Center